Tibet Duo Rui Pharmaceutical Co., Ltd. (SHE:301075)
China · Delayed Price · Currency is CNY 48.53
+0.25 (0.52%)
Jul 29, 2026, 4:00 PM EDT
SHE:301075 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 137.16 | 154.18 | 240.63 | 334.3 | 401.05 | 529.62 |
Revenue Growth | -43.00% | -35.93% | -28.02% | -16.64% | -24.27% | 8.05% |
Gross Profit Gross Profit Growth | 0.96 | 6.78 | 91.8 | 228.11 | 308.37 | 469.19 |
Operating Income Operating Income Growth | -111.94 | -116.9 | -87.81 | -2.57 | 1.81 | 62.38 |
Net Income Net Income Growth | -100.54 | -102.17 | -62.67 | 18.85 | 20.5 | 68.51 |
Earnings Per Share EPS Growth | -1.27 | -1.29 | -0.79 | 0.24 | 0.26 | 1.05 |
EPS Growth | - | - | - | -7.69% | -75.24% | -31.37% |
| Fiscal Year | FY 2025 | FY 2024 |
|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Preparations Preparations Growth | 55.36 | 186.79 |
Intermediate Intermediate Growth | 38.96 | 38 |
Active Pharmaceutical Ingredient (api) Active Pharmaceutical Ingredient (api) Growth | 49.74 | 10.32 |
Others Others Growth | 10.11 | 5.51 |
Total Total Growth | 154.18 | 240.63 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 65.44 | 105.32 | 403.81 | 482.84 | 505.76 | 610.93 |
Total Debt Total Debt Growth | 425.33 | 432.06 | 538.5 | 180.12 | 101.24 | 20.48 |
Net Cash (Debt) Net Cash Growth | -359.88 | -326.74 | -134.69 | 302.72 | 404.53 | 590.45 |
Net Cash Growth | - | - | - | -25.17% | -31.49% | 750.31% |
Net Cash Per Share Net Cash Per Share Growth | -4.55 | -4.13 | -1.70 | 3.85 | 5.13 | 9.05 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -66.45 | -45.83 | -67.18 | 12.41 | 1.13 | 48.15 |
Capital Expenditures CapEx Growth | -122.09 | -101.82 | -40.92 | -23.69 | -32.73 | -5.35 |
Free Cash Flow Free Cash Flow Growth | -188.54 | -147.65 | -108.09 | -11.28 | -31.6 | 42.8 |
Free Cash Flow Growth | - | - | - | - | - | 233.99% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 0.70% | 4.40% | 38.15% | 68.24% | 76.89% | 88.59% |
Operating Margin | -81.61% | -75.82% | -36.49% | -0.77% | 0.45% | 11.78% |
Pretax Margin | -92.93% | -85.20% | -35.64% | 6.66% | 5.24% | 13.84% |
Profit Margin | -73.30% | -66.27% | -26.04% | 5.64% | 5.11% | 12.93% |
FCF Margin | -137.46% | -95.77% | -44.92% | -3.37% | -7.88% | 8.08% |
| Fiscal Year | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|
| Period Ending | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.125 | - | 0.625 |
Dividend Per Share Growth | - | - | - |
Dividend Yield | 0.47% | - | 1.65% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | 113.18 | 126.19 | 45.44 |
P/FCF Ratio | - | - | - | - | - | 72.72 |
PS Ratio | 27.94 | 30.56 | 5.90 | 6.38 | 6.45 | 5.88 |